Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Annita‐Ioanna Gkioka"'
Autor:
Annita-Ioanna Gkioka, Alexandros Gkiokas, Alexandros Alexandropoulos, Mavra Papadatou, Aspasia Koudouna, Vasilliki Bartzi, Thomai-Marina Tryfou, Marie Christine Kyrtsonis
Publikováno v:
HemaSphere, Vol 7, p e35250bc (2023)
Externí odkaz:
https://doaj.org/article/348b6c46a39f4227a271b0b2089f6f47
Autor:
Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Sosana Delimpasi, Emmanouil Spanoudakis, Vasiliki Labropoulou, Ioannis Ntanasis‐Stathopoulos, Annita‐Ioanna Gkioka, Nikos Giannakoulas, Nikolaos Kanellias, Theodosia Papadopoulou, Aggeliki Sevastoudi, Eyrydiki Michalis, Maria Papathanasiou, Maria Kotsopoulou, Anastasia Sioni, Theodora Triantafyllou, Aikaterini Daiou, Mavra Papadatou, Marie‐Christine Kyrtsonis, Anastasia Pouli, Ioannis Kostopoulos, Evgenia Verrou, Meletios‐Athanasios Dimopoulos, Evangelos Terpos
Publikováno v:
American Journal of Hematology. 98:730-738
Autor:
Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Sosana Delimpasi, Emmanouil Spanoudakis, Vassiliki Labropoulou, Ioannis Ntanasis-Stathopoulos, Annita Ioanna Gkioka, Nikolaos Giannakoulas, Nikolaos Kanellias, Aggeliki Sevastoudi, Evridiki Michali, Maria Papathanasiou, Maria Kotsopoulou, Anastasia Sioni, Theodora Triantafyllou, Mavra Papadatou, Ioannis V Kostopoulos, Evgenia Verrou, Meletios-Athanasios Dimopoulos, Evangelos Terpos
Publikováno v:
Blood. 140:4386-4387
Autor:
Alexandros Gkiokas, Annita Ioanna Gkioka, Mavra Papadatou, Alexandros Alexandropoulos, Vasiliki Bartzi, Marie-Christine Kyrtsonis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S130-S131
Autor:
Aspasia Koudouna, Aikaterini Bitsani, Theodoros Iliakis, Vasiliki Bartzi, Maria Dimou, Annita Ioanna Gkioka, Panayiotis Panayiotidis, Mavra Papadatou, Vasileios Pardalis, Alexandros Gkiokas, Marie-Christine Kyrtsonis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S85-S86
Background Lenalidomide refractoriness constitutes an adverse factor of survival in MM as Lenalidomide relapsing/resistant patients were reported to respond difficultly to next treatment line. Lenalidomide is widely administered in doublet, triplet,
Autor:
Panayiotis Panayiotidis, Vasiliki Bartzi, Maria Dimou, Nora Vyniou, Niki Rougkala, Annita Ioanna Gkioka, Panagiotis Repousis, Theodoros Iliakis, Marie-Christine Kyrtsonis, Evangelos Asmanis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e160-e161
Autor:
Niki Rougkala, Annita Ioanna Gkioka, Aspasia Koudouna, Theodoros Iliakis, Thomais Tryfou, Maria Dimou, Marie-Christine Kyrtsonis, Paraskevi Papaioannou, Ioannis Grafakos, Aikaterini Bitsani, Panayiotis Panayiotidis, Vasileios Pardalis, Panagiotis Repousis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e117
Autor:
Gerasimos Pangalis, Aikaterini Bitsani, Annita Ioanna Gkioka, Ioannis Grafakos, Paraskevi Papaioannou, Argyrios Tsantes, Styliani I. Kokori, Thommais Tryfou, Panayiotis Panayiotidis, Sotirios Sachanas, Konstantina Chamoulkou, Anastasia Kopsaftopoulou, Maria Dimou, Panagiotis Repousis, Aspasia Koudouna, Marie-Christine Kyrtsonis, Dimitrios Maltezas
Publikováno v:
Blood. 132:5547-5547
CLL is a frequent and usually indolent disease that require only follow-up in about 2/3 of patients while the rest 1/3 of patients are symptomatic, have a worse outcome and need to be treated. The role of angiogenesis in CLL prognosis remains unclear
Autor:
Annita Ioanna Gkioka, Theodoros Iliakis, Anastasia Kopsaftopoulou, Maria Dimou, Aspasia Koudouna, Kallirroi Tsalimalma, Marie-Christine Kyrtsonis, Paraskevi Papaioannou, Petros P. Sfikakis, Nikolitsa Kafassi, Aikaterini Bitsani, Panayiotis Panayiotidis, Ioannis Grafakos, Konstantina Chamoulkou
Publikováno v:
Blood. 132:5584-5584
SMM may have an indolent course and remain stable for years; however, some patients evolve to MM requiring treatment within two years or less. To timely recognize these patients, three biomarkers (FLCR>100, ≥1 osteolysis and ≥60% plasma cell bone
Autor:
Pavlina Konstantinidou, Celia Suriu, Chezi Ganzel, Panagiotis Zikos, Gabriel Fakinos, Ariel Aviv, Adir Shaulov, Theodora Triantafyllou, Aristea-Maria Papanota, Meletios A. Dimopoulos, Yael C Cohen, Anna Christoforidou, Chrysavgi Lalayianni, Marie-Christine Kyrtsonis, Yuliana Vaxman, Eirini Katodritou, Achilles Anagnostopoulos, Chrysanthi Vadikoliou, Efstathios Kastritis, Evgenia Verrou, Vasiliki Palaska, Zektser Miri, Michalis Michael, Dimitris Maltezas, Annita‐Ioanna Gkioka, Evangelos Terpos, Maria Gavriatopoulou, Anastasia Pouli, Sosana Delimpasis, Katrin Tzafarti, Noa Lavi, Irit Avivi, Moshe E. Gatt
Publikováno v:
Blood. 132:3295-3295
Macrofocal Multiple Myeloma (MFMM) has been described as a distinct entity of Multiple Myeloma (MM) characterized by young age, lytic lesions and limited bone marrow infiltration by clonal plasma cells (BMPCs), in the absence of other features of sym